Menu

Blog

May 25, 2020

First Human Trial Of Possible COVID-19 Vaccine Triggers Rapid Immune Response, Few Side-Effects

Posted by in categories: biotech/medical, genetics

WUHAN, China — As the worldwide number of COVID-19 cases reaches five million, the search for a vaccine has taken an important step forward. Researchers say the first human trial of a possible vaccine has been found to be safe and may effectively fight the virus.

Scientists in China say 108 healthy adults were given a dose of adenovirus type 5 vectored COVID-19 (Ad5-nCoV) during the trial. The drug uses a weakened strain of the common cold (adenovirus) to deliver genetic material which codes itself to find the protein in SARS-CoV-2 — the virus that causes COVID-19. These coded cells then head to the lymph nodes where the immune system creates antibodies that can recognize the virus and attack it.

“These results represent an important milestone. The trial demonstrates that a single dose of the new adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells in 14 days,” Professor Wei Chen of the Beijing Institute of Biotechnology said in a statement.

Comments are closed.